Reacting to the FDA's extension by three months of the PDUFA date for Tegsedi (inotersen), Akcea Therapeutics Inc. CEO Paula Soteropoulos said the company does "not see the potential that this brings an advisory committee into the picture at all," and the shift by regulators was "purely [due to] the volume of data they have to go through."